Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04380337 · ClinicalTrials.gov registry record · Phase 2
Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT04380337: Completed Phase 2 study, sponsored by Stanford University.
NCT04380337 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04380337, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of the research is to evaluate whether both chemotherapy and radiotherapy can lead to higher rates of clinical complete response leading to organ preservation in human subjects with cancer. The objective is to learn if this treatment approach may safely be used as an alternative to the standard treatment for rectal cancer and to know the quality-of-life in these patients.
Interventions
- DRUG FOLFOX regimen
- RADIATION IMRT
- DRUG XELOX
- DRUG FOLFOXIRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2020-05-21 |
| Est. Completion | 2024-01-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04380337
The ClinicalTrials.gov registry entry for NCT04380337 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which FOLFOX regimen is the first listed.
NCT04380337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04380337 about?
NCT04380337 is a clinical study titled "Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer". The purpose of the research is to evaluate whether both chemotherapy and radiotherapy can lead to higher rates of clinical complete response leading to organ preservation in human subjects with cancer. The objective is to learn if this treatment approach may safely be used as an alternative to the s...
What is the current status of trial NCT04380337?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2020-05-21. Estimated completion is 2024-01-17.
What interventions are being tested in trial NCT04380337?
The interventions under investigation include: FOLFOX regimen (DRUG), IMRT (RADIATION), XELOX (DRUG), FOLFOXIRI (DRUG).
Who is sponsoring clinical trial NCT04380337?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.